JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
